Seroatlas · Human Serome Atlas

PLAU

Urokinase-type plasminogen activator

Also known as: UPA, URK, UROK_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P00749
Gene
PLAU
Ensembl
ENSG00000122861
Chromosome
10
Canonical length
431 aa
Protein class
Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins
Subcellular location
Golgi apparatus,Vesicles
Secretome location
Secreted to blood

OverviewNCBI Gene

This gene encodes a secreted serine protease that converts plasminogen to plasmin. The encoded preproprotein is proteolytically processed to generate A and B polypeptide chains. These chains associate via a single disulfide bond to form the catalytically inactive high molecular weight urokinase-type plasminogen activator (HMW-uPA). HMW-uPA can be further processed into the catalytically active low molecular weight urokinase-type plasminogen activator (LMW-uPA). This low molecular weight form does not bind to the urokinase-type plasminogen activator receptor. Mutations in this gene may be associated with Quebec platelet disorder and late-onset Alzheimer's disease. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Jan 2016]

Canonical amino-acid sequenceUniProt

431 residues, UniProt reviewed canonical sequence.

>P00749|PLAU
     1  MRALLARLLL CVLVVSDSKG SNELHQVPSN CDCLNGGTCV SNKYFSNIHW CNCPKKFGGQ
    61  HCEIDKSKTC YEGNGHFYRG KASTDTMGRP CLPWNSATVL QQTYHAHRSD ALQLGLGKHN
   121  YCRNPDNRRR PWCYVQVGLK LLVQECMVHD CADGKKPSSP PEELKFQCGQ KTLRPRFKII
   181  GGEFTTIENQ PWFAAIYRRH RGGSVTYVCG GSLISPCWVI SATHCFIDYP KKEDYIVYLG
   241  RSRLNSNTQG EMKFEVENLI LHKDYSADTL AHHNDIALLK IRSKEGRCAQ PSRTIQTICL
   301  PSMYNDPQFG TSCEITGFGK ENSTDYLYPE QLKMTVVKLI SHRECQQPHY YGSEVTTKML
   361  CAADPQWKTD SCQGDSGGPL VCSLQGRMTL TGIVSWGRGC ALKDKPGVYT RVSHFLPWIR
   421  SHTKEENGLA L

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PLAU can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.3
Highest tissue expression
120 nTPM

Expression across tissuesHPA

Tissue

  • urinary bladder: 120 nTPM
  • kidney: 93 nTPM
  • adipose tissue: 54 nTPM
  • appendix: 39 nTPM
  • spleen: 38 nTPM
  • placenta: 34 nTPM

Single-cell type

  • epididymal basal cells: 1,855 nCPM
  • ocular epithelial cells: 795 nCPM
  • urothelial cells: 234 nCPM
  • endometrial secretory cells: 232 nCPM
  • neutrophils: 124 nCPM
  • decidual stromal cells: 101 nCPM

Immune cell

  • neutrophil: 2.1 nTPM
  • plasmacytoid DC: 2 nTPM
  • myeloid DC: 1.1 nTPM
  • classical monocyte: 0.1 nTPM
  • total PBMC: 0.1 nTPM
  • basophil: 0 nTPM

Brain region

  • cerebral cortex: 16 nTPM
  • pons: 7.5 nTPM
  • thalamus: 6.2 nTPM
  • white matter: 5.7 nTPM
  • choroid plexus: 5 nTPM
  • medulla oblongata: 3.9 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PLAU.

Disease | AllUniProt

Conditions PLAU is implicated in, by any mechanism.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 158 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Quebec platelet disorder

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.85
gnomAD pLI
0
gnomAD missense Z
0.66
DepMap mean gene effect
0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PLAU in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PLAU as an antibody target. Whether an autoantibody or antibody against PLAU could matter depends on whether native PLAU is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PLAU is annotated as secreted, so native PLAU circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label PLAU as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PLAU. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...